 MindMed NASDAQ: MNMD NEO: MMED, a clinical-stage biotech company that is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, announced on Dec. 21 that the Food and Drug Administration FDA has placed a clinical hold on its IND submission intended to support the initiation of a Phase 2b trial of lysergic acid diethylamide LSD for the treatment of generalized anxiety disorder GAD. Additional detail regarding the FDAs decision is expected within 30 days. 